Skip to main content
Manali K. Kamdar on Muck Rack

Manali K. Kamdar

As seen in: Nature, The Lancet, Healio, Journal of Clinical Oncology, ONCOLOGY journal, OncLive, Targeted Oncology, Oncology Tube, CGTLive
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Manali K.

Contact Manali K., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Clinical outcomes of CD3xCD20 bispecific antibodies in patients with central nervous system involvement by lymphoma Original

|
By Karan L. Chohan, James Godfrey, Lorenzo Falchi, Manali K. Kamdar, Ajay Major, Wendy O. Dixon, Jennifer Crombie, Reid W. Merryman, Gilles Salles, Amy Ayers, Ayushi Chauhan, Alex Herrera, Álex Herrera, Geoffrey Shouse, Sairah Ahmed, Yazeed Sawalha, Rina L. Welkie, Steven Bair, Sonia Godbole, Omnia Farahat
| Nature Verified
Dear Editor, Despite recent advances in the treatment of systemic aggressive B-cell non-Hodgkin lymphomas (B-NHL), central nervous system (CNS) involvement remains a therapeutic challenge and is associated with dismal outcomes [1]. Chimeric antigen receptor (CAR) T-cell therapy achieves high overall response rates (ORR) in patients with CNS involvement, but responses are often short-lived (1-year progression-free survival (PFS) of 16–48%) [2,3,4,5].
Open in Who Shared View Duplicates (2) Issue with article?

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton’s tyrosine kinase inhibitor therapy

|
By Yucai Wang, Melissa Larson, Steven Hwang, Diego Villa, Laveniya Kugathasan, Anita Kumar Verified, Ashlee Joseph, Taylor Brooks, Brian Hill, David Bond, Kami J. Maddocks, Alexey B. Danilov, Jia Ruan, Imran Nizamuddin, Brad S. Kahl, Natalie Grover Verified, Georgios Pongas, Izidore S. Lossos, Evguenia Ouchveridze, Aung M. Tun, Firas Baidoun, Muhamad Alhaj Moustafa, Zoey Harris, Javier Muñoz, Philip Young, Craig Portell, Patrick M Reagan, Christine Ryan, Reid W. Merryman, Arash Velayati, Drew Gerber, Preetesh Jain, Michael Wang, Eric Mou, Lauren G. Banaszak, Priyanka A. Pophali, Anthony Stack, Marcus Messmer, Mayur Narkhede, Amitkumar Mehta, Nilanjan Ghosh, Rahul S Bhansali, Stefan K. Barta, Manali K. Kamdar, Jacob L. Anna, Reem Karmali, Matthew J. Maurer, James R. Cerhan, Jonathon Cohen, Peter Martin, Christine Argao, Nazneen B. Khan, I. Brian Greenwell, Sabarish R. Ayyappan, Tamara K. Moyo, Alexander V. Stanisic
| Nature Verified
Abstract Addition of Bruton’s tyrosine kinase inhibitor (BTKi) to first-line (1 L) bendamustine-rituximab (BR) improved progression-free survival (PFS) in patients with mantle cell lymphoma (MCL) in the SHINE and ECHO trials. We investigated whether sequential treatment with 1 L BR and second-line (2 L) BTKi can result in similar cumulative PFS compared to BR-BTKi combination therapy, using a multicenter cohort of 755 patients treated with 1 L BR between 2014 and 2020.
Open in Who Shared Issue with article?

Krina K. Patel, MD, MSc

|
By Manali K. Kamdar, Wei Ying Jen, BM BCh, M Sp Med
| ONCOLOGY journal Verified
ByKrina K. Patel, MD, MSc,Manali Kamdar, MD,Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting. Current FDA expectations may allow patients to return to their community physicians at 2 weeks after administration of anitocabtagene autoleucel. Based on its mechanism of action, anito-cel may cause fewer instances of cytokine release syndrome and delayed toxicities vs other therapies.
Open in Who Shared Issue with article?
See all 44 licensed articles (81 Total)